Status:
UNKNOWN
Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation
Lead Sponsor:
University of Khartoum
Collaborating Sponsors:
National Center for Kidney Diseases and Surgery
Conditions:
Kidney Transplant Rejection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Kidney transplantation is the best available treatment option for patients with end stage renal disease. However, kidney transplantation requires life-long use of immunosuppressive medication. Because...
Eligibility Criteria
Inclusion
- Adult end-stage renal disease patients
- First living donor kidney transplant.
- Moderate immunological risk.
Exclusion
- Low immunological risk (HLA mismatches 000/100/010/110 with negative PRA).
- High immunological risk (child to mother or husband to wife transplant, 2 DR mismatches).
- Known hypersensitivity to any of the study medication.
Key Trial Info
Start Date :
March 21 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 21 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03789006
Start Date
March 21 2018
End Date
March 21 2024
Last Update
January 3 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Doctor Salma Center for Kidney Diseases
Khartoum, Sudan, 11111